X
KEY PRODUCTS
Details:
KMN-159 is a potent, stable, and a highly selective EP4 receptor agonist that stimulates osteogenic activity. It is being evaluated for the treatment of osteoporosis.
Lead Product(s): KMN-159
Therapeutic Area: Musculoskeletal Product Name: KMN-159
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Lead Product(s): KMN-159,Collagen
Therapeutic Area: Musculoskeletal Product Name: KMN-159
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: NIDCR
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 16, 2021
Cophex 2024
Not Confirmed
Contact SupplierDetails:
The funding will be used to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.
Lead Product(s): Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: SBIR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 08, 2020
Cophex 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
